- The disease
- Travellers' diarrhoea (TD) is an infectious gastrointestinal illness affecting people travelling to regions with higher rates of enteric pathogens, most commonly caused by enterotoxigenic Escherichia coli (ETEC). It is among the most frequent travel-related illnesses globally. There is currently no FDA-approved vaccine or oral prophylactic drug specifically indicated for TD prevention, though antibiotics are sometimes used off-label. Bismuth subsalicylate has limited preventive evidence but is not FDA-approved for this indication.
- What the asset is trying to do
- IMM-124E, sold under the brand name Travelan, is a prescription oral product derived from hyperimmune bovine colostrum — colostrum collected from cows that have been immunised to produce high levels of antibodies against enteric pathogens, including ETEC. The product is taken orally and is intended to deliver pathogen-specific antibodies directly to the gastrointestinal tract to reduce infection. This approach differs from systemic antibiotic prophylaxis or vaccines in that it delivers passive immunity locally in the gut rather than inducing a host immune response.
- What the trial is measuring, and why it matters
- The lead Phase 2 trial (NCT05933525) used a controlled human infection model (CHIM), in which consenting healthy volunteers are deliberately exposed to a defined dose of an enteric pathogen under clinical supervision. This model allows direct measurement of whether the treatment reduces rates of diarrhoea and infection compared with placebo in a controlled setting. Immuron has disclosed that a clinical study report (CSR) from this trial has been submitted to the FDA and that an End-of-Phase 2 meeting with the FDA has been requested (per Immuron ASX announcement, Strategic Update and HY26 Results, 2026-02-25).
- Efficacy benchmarks in this setting
- There is no FDA-approved oral prophylactic specifically for travellers' diarrhoea, so direct regulatory benchmarks in this exact setting are limited. For context, a published meta-analysis of antibiotic prophylaxis for TD reported protective efficacy in the range of approximately 80-90% relative reduction in TD incidence, though these studies varied substantially in design, pathogen exposure, and population (per Riddle et al, Journal of Travel Medicine, 2017). Bismuth subsalicylate showed roughly 65% protective efficacy against TD in earlier controlled trials (per DuPont et al, JAMA, 1980). It should be noted that figures from early-phase or small controlled studies of IMM-124E are not statistically comparable to these larger, later-phase or approved-therapy datasets.